title: [Self defense instead of offense - Immunotherapy in lung cancer].
abstract: Lung cancer is the leading cause of cancer death worldwide and also in Hungary, therefore new therapeutic strategies are of great importance. Among immunotherapeutic approaches immune checkpoint inhibition appears to be the most promising. Recent studies have shown efficacy of immunotherapy, especially in squamous cell lung cancer, which is a big step forward in the treatment of this histological subtype. Unlike in the molecularly targeted therapies, the patient selection method has not yet been developed, although some studies indicate the predictive value of tumor cell PD-L1 immunopositivity, especially in lung adenocarcinoma. Introduction of immunotherapy carries challenge for clinicians regarding the radiological assessment of therapeutic efficiency as well as the management of side effects of new profile. The favorable results of recent studies, however, provide hope in this malignancy still presenting a major therapeutic challenge.
authors.affiliation: Tumorbiológiai Osztály - Semmelweis Egyetem, Országos Korányi Tbc és Pulmonológiai Intézet, Budapest, Hungary. drmoldvay@hotmail.com.
authors.forename: Judit
authors.initials: J
authors.lastname: Moldvay
authors.affiliation: VIII. Tüdõbelosztály, Országos Korányi Tbc és Pulmonológiai Intézet, Budapest, Hungary.
authors.forename: Gyula
authors.initials: G
authors.lastname: Ostoros
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung; D006801:Humans; D006814:Hungary; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D061026:Programmed Cell Death 1 Receptor